顺铂在亚洲印度癌症患者中的人群药代动力学

Harish K. Kaushik, Vijay Kumar, Satish B. Kumar, N. Reddy, V. K. Raghavaiah, K. Devarakonda
{"title":"顺铂在亚洲印度癌症患者中的人群药代动力学","authors":"Harish K. Kaushik, Vijay Kumar, Satish B. Kumar, N. Reddy, V. K. Raghavaiah, K. Devarakonda","doi":"10.3109/10601330903252206","DOIUrl":null,"url":null,"abstract":"The aim of this study was to describe population pharmacokinetics of cisplatin in an Indian cancer population. Dosage adjustment based on individual pharmacokinetic parameters is of considerable importance for effective and safe use of drugs. Extensive work on cisplatin and other was carried out in different cancer patient populations, but no data are available in Indian cancer patients. In the present study 154 steady state concentrations of cisplatin were analyzed from 46 patients. Pharmacostatistical work was done by using NONMEM. The covariates evaluated in this study were age, body weight, height, sex, and creatinine clearance. The model found to best describe the data following the FO and FOCE method was: Clearance (CL) = θ1*(CLCR/74.92) *EXP (η1) and Volume (V) = {θ2 *(AGE/52.3) + θ3*(BSA/1.55)}*EXP (η2). The final model estimates of CL and V estimated by FO method were 3.02 L/h and 2.72 L, respectively, and by FOCE method were 3.39 L/h and 4.48 L, respectively. These parameters are utilized for individualizing the loading and maintenance doses in pediatric patients.","PeriodicalId":10446,"journal":{"name":"Clinical Research and Regulatory Affairs","volume":"10 1","pages":"84 - 92"},"PeriodicalIF":0.0000,"publicationDate":"2009-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Population pharmacokinetics of cisplatin in Asian Indian cancer patients\",\"authors\":\"Harish K. Kaushik, Vijay Kumar, Satish B. Kumar, N. Reddy, V. K. Raghavaiah, K. Devarakonda\",\"doi\":\"10.3109/10601330903252206\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The aim of this study was to describe population pharmacokinetics of cisplatin in an Indian cancer population. Dosage adjustment based on individual pharmacokinetic parameters is of considerable importance for effective and safe use of drugs. Extensive work on cisplatin and other was carried out in different cancer patient populations, but no data are available in Indian cancer patients. In the present study 154 steady state concentrations of cisplatin were analyzed from 46 patients. Pharmacostatistical work was done by using NONMEM. The covariates evaluated in this study were age, body weight, height, sex, and creatinine clearance. The model found to best describe the data following the FO and FOCE method was: Clearance (CL) = θ1*(CLCR/74.92) *EXP (η1) and Volume (V) = {θ2 *(AGE/52.3) + θ3*(BSA/1.55)}*EXP (η2). The final model estimates of CL and V estimated by FO method were 3.02 L/h and 2.72 L, respectively, and by FOCE method were 3.39 L/h and 4.48 L, respectively. These parameters are utilized for individualizing the loading and maintenance doses in pediatric patients.\",\"PeriodicalId\":10446,\"journal\":{\"name\":\"Clinical Research and Regulatory Affairs\",\"volume\":\"10 1\",\"pages\":\"84 - 92\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-11-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Research and Regulatory Affairs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3109/10601330903252206\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research and Regulatory Affairs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/10601330903252206","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

摘要

本研究的目的是描述顺铂在印度癌症人群中的群体药代动力学。基于个体药代动力学参数的剂量调整对于药物的有效和安全使用具有相当重要的意义。在不同的癌症患者群体中进行了大量关于顺铂和其他药物的研究,但没有关于印度癌症患者的数据。本研究分析了46例患者的154例稳态顺铂浓度。采用NONMEM进行药物统计工作。本研究评估的协变量为年龄、体重、身高、性别和肌酐清除率。根据FO和FOCE方法发现的最能描述数据的模型为:Clearance (CL) = θ1*(CLCR/74.92) *EXP (η1), Volume (V) = {θ2 *(AGE/52.3) + θ3*(BSA/1.55)}*EXP (η2)。FO法估算的CL和V最终模型估计值分别为3.02 L/h和2.72 L, FOCE法估算的CL和V最终模型估计值分别为3.39 L/h和4.48 L。这些参数用于个性化儿科患者的负荷和维持剂量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Population pharmacokinetics of cisplatin in Asian Indian cancer patients
The aim of this study was to describe population pharmacokinetics of cisplatin in an Indian cancer population. Dosage adjustment based on individual pharmacokinetic parameters is of considerable importance for effective and safe use of drugs. Extensive work on cisplatin and other was carried out in different cancer patient populations, but no data are available in Indian cancer patients. In the present study 154 steady state concentrations of cisplatin were analyzed from 46 patients. Pharmacostatistical work was done by using NONMEM. The covariates evaluated in this study were age, body weight, height, sex, and creatinine clearance. The model found to best describe the data following the FO and FOCE method was: Clearance (CL) = θ1*(CLCR/74.92) *EXP (η1) and Volume (V) = {θ2 *(AGE/52.3) + θ3*(BSA/1.55)}*EXP (η2). The final model estimates of CL and V estimated by FO method were 3.02 L/h and 2.72 L, respectively, and by FOCE method were 3.39 L/h and 4.48 L, respectively. These parameters are utilized for individualizing the loading and maintenance doses in pediatric patients.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信